{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:56:48Z","timestamp":1791633408136,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-009"],"award-info":[{"award-number":["2022-PUMCH-D-009"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-009"],"award-info":[{"award-number":["2022-PUMCH-D-009"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-009"],"award-info":[{"award-number":["2022-PUMCH-D-009"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-009"],"award-info":[{"award-number":["2022-PUMCH-D-009"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-009"],"award-info":[{"award-number":["2022-PUMCH-D-009"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-009"],"award-info":[{"award-number":["2022-PUMCH-D-009"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["No. Z201100005520022,23, 25-27"],"award-info":[{"award-number":["No. Z201100005520022,23, 25-27"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["No. Z201100005520022,23, 25-27"],"award-info":[{"award-number":["No. Z201100005520022,23, 25-27"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["No. Z201100005520022,23, 25-27"],"award-info":[{"award-number":["No. Z201100005520022,23, 25-27"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2021YFC2501300"],"award-info":[{"award-number":["2021YFC2501300"]}]},{"name":"Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2021YFC2501300"],"award-info":[{"award-number":["2021YFC2501300"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count&lt;100\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Demographic characteristics, platelet count, clinical manifestations, disease activity, and autoantibody profiles were collected at baseline. Relapse was defined as the loss of remission. Bone marrow aspirate reports were also collected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 350 SLE-TP patients with complete follow-up data, 194 (55.4%) were aPLs positive. At baseline, SLE-TP patients with aPLs had lower baseline platelet counts (61.0\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L vs. 76.5\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L,\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001), and a higher proportion of moderate to severe cases (24.2% vs. 14.1% ; 18.0% vs. 8.3%,\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001). SLE-TP patients with aPLs also had lower platelet counts at their lowest point (37.0\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L vs. 51.0\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). In addition, thean increasing number of aPLs types was associated with a decrease in the baseline and minimum values of platelets (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). During follow-up, SLE-TP carrying aPLs had a higher relapse rate (58.2% vs. 44.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009) and a lower complete response (CR) rate. As the types of aPLs increased, the relapse rate increased, and the CR rate decreased. Furthermore, there was no significant difference in the ratio of granulocytes to red blood cells (G\/E), the total number of megakaryocyte and categories.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SLE-TP patients with positive aPLs had more severe disease a lower remission rate but a higher relapse rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-024-03305-w","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:01:48Z","timestamp":1710212508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"9","key":"3305_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for systemic Lupus Erythematosus. Ann Rheum Dis. 2019;78(9):1151\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3305_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/rheumatology\/39.4.399","volume":"39","author":"CC Mok","year":"2000","unstructured":"Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford). 2000;39(4):399\u2013406.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3305_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.amjms.2019.03.002","volume":"357","author":"Z Chen","year":"2019","unstructured":"Chen Z, Zhong H, Dong G. Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: a systematic review and Meta-analysis. Am J Med Sci. 2019;357(6):461\u201367.","journal-title":"Am J Med Sci"},{"issue":"4","key":"3305_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jtha.2022.12.002","volume":"21","author":"DM Salet","year":"2023","unstructured":"Salet DM, Bekkering S, Middeldorp S, et al. Targeting Thromboinflammation in Antiphospholipid Syndrome. J Thromb Haemost. 2023;21(4):744\u201357.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"3305_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11926-014-0494-8","volume":"17","author":"B Artim-Esen","year":"2015","unstructured":"Artim-Esen B, Diz-K\u00fc\u00e7\u00fckkaya R, \u0130nan\u00e7 M. The significance and management of Thrombocytopenia in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2015;17(3):14.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"3305_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1177\/0961203313499086","volume":"22","author":"M Li","year":"2013","unstructured":"Li M, Zhang W, Leng X, et al. Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus. 2013;22(11):1192\u20139.","journal-title":"Lupus"},{"issue":"6","key":"3305_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/0961203315625460","volume":"25","author":"J Zhao","year":"2016","unstructured":"Zhao J, Bai W, Zhu P, et al. Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus. Lupus. 2016;25(6):652\u20137.","journal-title":"Lupus"},{"issue":"8","key":"3305_CR8","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai A-M, Alarc\u00f3n GS, et al. Derivation and validation of the systemic Lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"16","key":"3305_CR9","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190\u2013207.","journal-title":"Blood"},{"issue":"11","key":"3305_CR10","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"issue":"1","key":"3305_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13075-022-02901-y","volume":"24","author":"SM Ahn","year":"2022","unstructured":"Ahn SM, Choi E-J, Oh JS, et al. Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia. Arthritis Res Ther. 2022;24(1):213.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3305_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1177\/0961203316672926","volume":"26","author":"D Miranda-Hern\u00e1ndez","year":"2017","unstructured":"Miranda-Hern\u00e1ndez D, Cruz-Reyes C, Monsebaiz-Mora C, et al. Active haematological manifestations of systemic lupus erythematosus lupus are associated with a high rate of in-hospital mortality. Lupus. 2017;26(6):640\u20135.","journal-title":"Lupus"},{"issue":"6","key":"3305_CR13","doi-asserted-by":"publisher","first-page":"e32949","DOI":"10.1097\/MD.0000000000032949","volume":"102","author":"W Garra","year":"2023","unstructured":"Garra W, Carmi O, Kivity S, et al. Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag a case series and literature review. Medicine. 2023;102(6):e32949.","journal-title":"Medicine"},{"issue":"4","key":"3305_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0268-960X(93)90006-P","volume":"7","author":"DM Keeling","year":"1993","unstructured":"Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev. 1993;7(4):199\u2013207.","journal-title":"Blood Rev"},{"issue":"2","key":"3305_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3305_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1055\/s-0038-1649646","volume":"70","author":"M ME","year":"1993","unstructured":"ME M, Maclouf J, Carreras LO, et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost. 1993;70(4):667\u201371.","journal-title":"Thromb Haemost"},{"issue":"11","key":"3305_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1160\/TH13-02-0102","volume":"110","author":"A Verschoor","year":"2013","unstructured":"Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost. 2013;110(11):910\u20139.","journal-title":"Thromb Haemost"},{"issue":"02","key":"3305_CR18","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1055\/a-2087-0314","volume":"07","author":"SR Vils","year":"2023","unstructured":"Vils SR, Troldborg A, Hvas A-M, et al. Platelets and the lectin pathway of complement activation in patients with systemic Lupus Erythematosus or Antiphospholipid Syndrome. TH Open. 2023;07(02):e155\u201367.","journal-title":"TH Open"},{"issue":"9","key":"3305_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1002\/art.20434","volume":"50","author":"M Vega-Ostertag","year":"2004","unstructured":"Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum. 2004;50(9):2911\u20139.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3305_CR20","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/ATVBAHA.123.318978","volume":"43","author":"Z Tang","year":"2023","unstructured":"Tang Z, Shi H, Chen C, et al. Activation of platelet mTORC2\/Akt pathway by Anti-\u03b22GP1 antibody promotes thrombosis in Antiphospholipid Syndrome. Arterioscler Thromb Vasc Biol. 2023;43(10):1818\u201332.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03305-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T06:09:41Z","timestamp":1710482981000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03305-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03305-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3654425\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital (Approval number, JS-3386D).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}